Tissue Regeneration Systems (TRS) is a medical device company commercializing a breakthrough skeletal reconstruction and bone regeneration technology platform licensed from the Universities of Michigan and Wisconsin. Validated by numerous in vitro and in vivo studies, including several large animal trials with very promising long term resultss, the firms has completed required bench and animal testing and received 510K clearance from the FDA for technology platform and first commercial product. This platform has two novel and proprietary components. One: to utilize proprietary and scalable 3D printing methods to fabricate advanced skeletal reconstruction implants that have unique attributes. Bioresorbable over time, fully replacing themselves with natural bone and leaving no residual implanted device. Although their micro-architecture is porous to facilitate bone integration, this porosity is fully engineered so that the implant can bear significant load and support function, allowing for use in a broad range of complex procedures as an alternative to harvested bone. Using input from patient CT scans, their geometry can be custom constructed and, if necessary, adapted in the operating room to exactly replicate and replace missing bone anatomy. The firm's Affinity⢠coating technology allows TRS to integrate implants with an osteoconductive, mineral coating that enhances bone regeneration and proliferation into and throughout the porous implant. Affinity⢠has a plate-like nanostructure that resembles living bone and serves as an excellent substrate for adhesion of autologous cells and growth factors, such as BMP, which can be added intra-operatively and released in a controlled manner to accelerate new bone formati
